好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Reduction of treatment-limiting non-psychotic behavioral adverse events associated with levetiracetam (LEV): an open-label, prospective study of patients with epilepsy switching from LEV to brivaracetam (BRV) treatment
Epilepsy/Clinical Neurophysiology (EEG)
(-)
195
Authors/Disclosures
Joseph D'Souza, PhD (UCB Pharma)
PRESENTER 		No disclosure on file
Stephen L. Yates, PhD Dr. Yates has received personal compensation for serving as an employee of UCB Biosciences, Inc.. Dr. Yates has stock in UCB Biosciences, Inc..
Toufic Fakhoury, MD (St. Joseph Neurological Assicates) Dr. Fakhoury has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB pharma. Dr. Fakhoury has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai . Dr. Fakhoury has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aquestive therapeutics. Dr. Fakhoury has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Fakhoury has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Fakhoury has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. The institution of Dr. Fakhoury has received research support from Xenon. The institution of Dr. Fakhoury has received research support from Takeda.
No disclosure on file
No disclosure on file
Alexander H. Rajput, MD, FAAN (Royal Univ Hosp/division of Neuro) Dr. Rajput has received personal compensation in the range of $500-$4,999 for serving as a Peer reviewer with CQDM.